Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM6B | O15054 | 3/20 | 0.41 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | BRS3 | P32247 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28764741 | 0.89 | NAMPT (0.44) | KDM4CNAMPTCYP17A1ATRRAB9A | |
| SCHEMBL12190376 | 0.88 | NAMPT (0.49) | NAMPTCYP17A1ATRRAB9AIDO1 | |
| SCHEMBL535637 | 0.88 | KDM4C (0.58) | KDM4CNAMPTCYP17A1KDM6BKDM4D | |
| SCHEMBL950258 | 0.87 | ATR (0.53) | NAMPTCYP17A1ATRRAB9AIDO1 | |
| SCHEMBL5551442 | 0.87 | SIRT3 (0.47) | NAMPTCYP17A1ATRRAB9AIDO1 | |
| SCHEMBL2210869 | 0.86 | NAMPT (0.47) | NAMPTCYP17A1ATRRAB9AIDO1 | |
| SCHEMBL18522430 | 0.84 | NAMPT (0.50) | KDM4CNAMPTCYP17A1ATRRAB9A | |
| SCHEMBL3717883 | 0.83 | KDM4C (0.50) | KDM4CNAMPTKDM6BKDM4DIDO1 | |
| SCHEMBL3666785 | 0.82 | NAMPT (0.48) | NAMPTCYP17A1ATRRAB9AMETAP1 | |
| SCHEMBL2107971 | 0.82 | NAMPT (0.48) | NAMPTCYP17A1ATRRAB9AMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306677-A1 | COMPOSITIONS AND METHODS FOR MAKING HYBRID POLYPEPTIDES | YALE UNIVERSITY | 2022-09-29 | — | — | US | disclosed |
| WO-2020247605-A1 | COMPOSITIONS AND METHODS FOR MAKING HYBRID POLYPEPTIDES | YALE UNIVERSITY (US) | 2020-12-10 | — | — | WO | disclosed |
| US-9682953-B2 | Amide compounds, compositions and applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-06-20 | — | — | US | disclosed |
| US-9682953-B2 | Amide compounds, compositions and applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-06-20 | — | — | US | disclosed |
| US-9682953-B2 | Amide compounds, compositions and applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-06-20 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| CN-103958473-B | Amide compound, composition and application thereof | ADVINUS THERAPEUTICS LTD. (IN) | 2016-11-30 | — | — | CN | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-6521620-B1 | Suppressing tumors, especially breast cancers; antiproli-ferative agents; arthritis, vascular restenosis, psoriasis and angiogenesis; extremely low cytotoxicity | WARNER-LAMBERT COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-6455534-B2 | ANTIPROLIVERATIVE, -CARCINOGENIC AND -TUMOR AGENTS; MITOGENESIS-ACTIVATED PROTEIN KINASE INHIBITORS; NONCYTOTOXIC; BINDING WITH HIGH AFFINITY AT THE ADENOSINE TRIPHOSPHATE BINDING SITE OF THE KINASES | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| EP-1140905-A1 | HETEROAROMATIC AMIDES AS INHIBITOR OF FACTOR XA | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2001-10-04 | — | — | US | disclosed |
| US-6265410-B1 | ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| WO-2000039117-A1 | HETEROROAROMATIC AMIDES AS INHIBITOR OF FACTOR Xa | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
| US-6084095-A | INCLUDING 6-AMINO-4-(3-BROMOANILINO)PYRIDO(3,2-D)PYRIMIDINE; 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO (3,2-D)PYRIMIDINE; AND 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO(3,2-D)PYRIMIDINE; USEFUL IN TREATING PROLIFERATIVE DISEASES SUCH AS CANCER | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5654307-A | ANTICARCINOGENIC AGENTS, ANTIARTHRITIC AGENT, SKIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | KDM4C 3111/4885NAMPT 481/4885CYP17A1 649/4885 |
| US-20220306677-A1 | COMPOSITIONS AND METHODS FOR MAKING HYBRID POLYPEPTIDES | NSUN3, TARBP1, TRDMT1 | KDM4C 2458/4885NAMPT 1615/4885CYP17A1 4165/4885 |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | KDM4C 1773/4885NAMPT 2920/4885CYP17A1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.